Phathom Pharmaceuticals Revises Outlook, Investigation Notice Issued to Investors

Phathom Pharmaceuticals, a pharmaceutical company, has revised its revenue guidance for fiscal year 2026, reducing the upper limit of its projection. The company previously guided for revenue as high as $345 million, but the updated outlook now tops out at $325 million.

The adjustment reflects updated market assessments and internal evaluations. This revision led to a decline in the company's stock price, with PHAT shareholders experiencing the decrease in value.

Simultaneously, several law firms representing investors, including Levi & Korsinsky, have issued notices to investors regarding a pending investigation into Phathom Pharmaceuticals. The investigation is reportedly focused on the company's disclosures and related stock performance.

Earlier plans by Phathom Pharmaceuticals involved building out a sales force exceeding 290 representatives. The revised financial outlook may influence future strategic decisions regarding expansion and resource allocation.